New weekly shot could simplify diabetes care for millions
NCT ID NCT07055386
First seen Nov 21, 2025 · Last updated Jun 15, 2026 · Updated 24 times
Summary
This study tests two experimental injections, GZR102 (once a week) and GZR18 (every two weeks), in adults with type 2 diabetes whose blood sugar is not well controlled on current GLP-1 medications. About 90 Chinese participants will receive one of the two treatments to see which works better at lowering blood sugar and weight, and to check for side effects. The goal is to find a more convenient option for managing diabetes long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site 01
Beijing, China
Conditions
Explore the condition pages connected to this study.